EMA reminds pharma of post-Brexit continuity - for now

On the day that the UK leaves the European Union (EU), the European Medicines Agency (EMA) has reminded drugmakers that any major changes will not be seen for another 11 months.

Although the UK will become a third country to the EU on Saturday, a transition period will continue until December 31, 2020.

During this period, EU pharmaceutical law will remain applicable in the UK, and companies have until 2021 to make the necessary changes to ensure that their authorized medicines comply with EU law and can remain on the EU market.